January 6, 2026
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
January 6, 2026
search category
December 17, 2025
Transgene to Participate in Upcoming Investor Meetings
December 15, 2025
TG6050
December 11, 2025
teaser produits : tg6050
November 27, 2025
Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets
November 25, 2025
Announces the Temporary Suspension of Trading of its Shares on Euronext Paris
November 14, 2025
TG4050 at 2025 SITC: New Ph.I immunological data
November 12, 2025
VacDesignR®: a Tool for Optimizing Recombinant Poxvirus Vaccine Production
November 7, 2025
Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC
November 4, 2025
Third Quarter 2025 Financial Results
October 20, 2025
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
October 20, 2025
Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors
October 19, 2025
Pooled Safety Analysis of Modified Vaccinia Virus Ankara-based Therapeutic Vaccine Alone or in Combination in Cancer and Cervical Intraepithelial Neoplasia (CIN) Clinical Trials
October 13, 2025
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
October 3, 2025
Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025
September 24, 2025
TG6002 oncolytic vaccinia virusand chemotherapy synergy: apromising strategy for pancreaticductal adenocarcinoma
September 24, 2025
onglet presse releases
September 16, 2025
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data – Randomization to be Completed in Phase II Part in Q4 2025
August 7, 2025
A Pseudocowpox virus vector to generate human B cell-based vaccines
July 27, 2025
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025
July 23, 2025
Management committee
July 22, 2025
Sabine Tejpar
July 22, 2025
Ignacio Melero
July 22, 2025
Antoine Italiano
July 22, 2025
Fatima Cardoso
July 9, 2025
Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independant Director
July 4, 2025
Utilisation de l’analyseur xCELLigence RTCA eSight pour l’évaluation de la nouvelle plateforme de virus oncolytique de Transgene
June 19, 2025
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer
June 13, 2025
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
June 6, 2025
Listen to Prof. Ottensmeier explain the TG4050 Phase 1 data
June 3, 2025
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025
June 1, 2025
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccin TG4050
June 1, 2025
Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
May 22, 2025
Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
May 22, 2025
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050
May 22, 2025
Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 inresected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts)
May 22, 2025
A randomized phase II trial evaluating the combination of TG4001, a HPV16 therapeutic vaccineand avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic(R/M) HPV16-positive cervical or anogenital cancer
May 15, 2025
Transgene’s Combined General Meeting of May 15, 2025
May 7, 2025
Credits
May 2, 2025
teaser produits : Research & Innovation
May 2, 2025
teaser produits : mpox
May 2, 2025
teaser produits : placeholder
May 2, 2025
teaser produits : additionnal indication
April 24, 2025
Transgene Provides Business and Financial Update for Q1 2025
April 24, 2025
svg pipeline
April 24, 2025
Availability of Preparatory Documents for the Combined General Meeting of May 15, 2025
April 23, 2025
Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025
April 15, 2025
A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
April 10, 2025
Availability of Transgene’s 2024 Universal Registration Document (URD)
April 4, 2025
Our leadership
April 3, 2025
Simone STEINER
April 3, 2025
Corporate Governance
April 3, 2025
CG Governance and internal procedures
April 3, 2025
CG Management Committee
April 3, 2025
CG Board of Directors
April 1, 2025
Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations
March 31, 2025
Financial reports 2025
March 27, 2025
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine – Strong Outlook for 2025
March 11, 2025
Transgene to Participate in Upcoming Investor Meetings
February 6, 2025
Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
January 21, 2025
Transgene To Participate in the Biomed Forum Investor Conference
January 14, 2025
Transgene Announces Financial Calendar for 2025
November 7, 2024
Transgene Reports Business, Pipeline and Financial Update for Q3 2024
November 7, 2024
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
November 7, 2024
Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)
November 5, 2024
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Develpment
October 27, 2024
TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery
October 14, 2024
Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
October 7, 2024
Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
September 24, 2024
Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
